Showing posts with label Ovarian cancer. Show all posts
Showing posts with label Ovarian cancer. Show all posts

Tuesday, November 1, 2011

Ovarian Cancer Spread Fuelled By Abdominal Fat Cells


Fat cells in the omentum, a large fatty pad of tissue that drapes over the intestines in the abdomen, fuel the spread of ovarian cancer by providing nutrients and energy for rapid tumor growth, according to a new study published online in Nature Medicine at the weekend.
Study author Ernst Lengyel, professor of obstetrics & gynecology, the University of Chicago, told the press:
"The cells that make up the omentum contain the biological equivalent of jet fuel. They feed the cancer cells, enabling them to multiply rapidly."
He explained that the fatty tissue of the omentum is extraordinarily rich in energy-dense lipids, which provide a "lauching pad" and energy source for ovarian cancer cells, enabling the spread of this lethal disease.
Ovarian cancer is the fifth leading cause of cancer deaths in women, and it tends to spread to the omentum as opposed to distant organs. For the vast majority of women, by the time their ovarian cancer is diagnosed, it has already spread to the omentum, and tumors here often become bigger than the original cancer:
"Currently, it is unclear why tumor cells preferentially home to and proliferate in the omentum, yet omental metastases typically represent the largest tumor in the abdominal cavities of women with ovarian cancer," write the authors.
To try and find out more about the role of these fat cells in fuelling ovarian cancer spread, Lengyel and colleagues carried out a series of experiments using ovarian cancer cell cultures and live mice.
When they injected ovarian cancer cells into the abdomens of healthy mice, the cells took only 20 minutes to reach the omentum, showing they find their way there very quickly.
The researchers discovered that adipokines, a type of cell-to-cell signalling protein, inside the omentum were attracting the ovarian cancer cells. When they blocked these signals, the attraction reduced by at least 50%. In their paper they describe what they found:
"... primary human omental adipocytes promote homing, migration and invasion of ovarian cancer cells, and ... adipokines including interleukin-8 (IL-8) mediate these activities."
Once the cancer cells reach the omentum, they immediately set about making the tools that will enable them to make use of the nutrients and energy in the fatty tissue: they even reprogram the fat cells' metabolism to enable the "direct transfer of lipids from adipocytes to ovarian cancer cells".
In culture, the researchers found that the cancer cells also appear to be able to use the fat cells as a source of energy:
"... coculture induced lipolysis in adipocytes and [beta]-oxidation in cancer cells, suggesting adipocytes act as an energy source for the cancer cells."
It does not take very long for the cancer to transform the entire omentum into a solid mass of cancer cells.

Lengyel and colleagues discovered that a fatty acid binding protein, FABP4, which transports fat, may be very important to this process and could be a potential target for therapy.

They discovered this when they compared cells from primary ovarian cancer tissue to cells from tumors at the migration sites in the omentum.

They found the cancer cells next to the fat cells in the omentum produced high levels of FABP4, whereas cancer cells that were far away from the omentum fat cells did not produce any.

They showed that inhibiting FABP4 drastically reduced the transport of nutrients from the fat cells to the cancer cells in the omentum. It also slowed down the growth of tumors and their ability to generate new blood vessels.

"FABP4 deficiency substantially impaired metastatic tumor growth in mice, indicating that FABP4 has a key role in ovarian cancer metastasis," they conclude.

Lengyel and colleagues suggest fat metabolism may also be a factor in other cancers where there is a rich source of fat cells, such as breast cancer. And in the case of FABP4 specifically, it may be implicated in cancers that develop in the abdomen, and therefore:

"... FABP4 emerges as an excellent target in the treatment of intra-abdominally disseminating tumors, which preferentially metastasize to adipose tissue such as ovarian, gastric, and colon cancers."

Funds from the National Institutes of Health, the Burroughs Wellcome Fund, the Committee on Cancer Biology at the University of Chicago and Bears Care, the charitable beneficiary of the Chicago Bears Football Club, helped pay for the study.

Written by Catharine Paddock PhD

Friday, October 28, 2011

IVF May Be Tied To Ovarian Tumors Later In Life







A Dutch study suggests that stimulating the ovaries to produce eggs for in vitro fertilization or IVF, may increase the risk of developing ovarian tumors, some of which may become cancerous, later in life. Overall, the researchers found rates of non-fatal "borderline ovarian tumors" were increased four-fold and rates of malignant tumors were increased two-fold compared to other women seeking fertility treatment who did not undergo IVF.

However, while these relative risks sound alarming and large, concerned women should bear in mind that in absolute terms they are very small indeed and this is only a preliminary study. The researchers concluded that further studies with much larger numbers of participants are now needed to investigate this further.
Flora van Leeuwen, a professor at the Netherlands Cancer Institute in Amsterdam, and colleagues, write about their investigation in the 26 October online issue of Human Reproduction.

In vitro fertilization (IVF) is used to help couples having difficulty conceiving. The woman is given hormones to stimulate her ovaries to make eggs which are harvested and fertilized with the man's sperm in a test tube. The fertilized egg is then inserted into the woman's uterus where it hopefully results in a successful pregnancy.
The world's first "test tube" baby was Louise Brown, born in 1978 in Oldham, Greater Manchester, UK. The physiologist who helped her parents conceive through IVF was Robert G. Edwards who won the Nobel Prize in Physiology or Medicine in 2010 for developing the treatment.

However, although the treatment has been around for three decades, we know don't know if and to what extent the hormone stimulation may affect the risk of developing ovarian cancer.
So, for their preliminary study, Van Leeuwen and colleagues followed up a nationwide cohort of 19,146 women who received IVF treatment in the Netherlands between 1983 and 1995. For comparison, they also had data on 6,006 counterparts with similar fertility problems who did not undergo IVF. By cross-referring with disease registers and other sources, they managed to find enough complete data to do a risk analysis on 65% of the women.
They compared risks of developing ovarian malignancies in the IVF group with risks in the general population and the non-IVF comparison group.
The results showed that:
  • After a median follow-up of 14.7 years, the risk of borderline ovarian tumors was higher in the IVF group than in the general population (Standardized Incidence Ratio, SIR, was 1.76, with Confidence Interval CI ranging from 1.16 to 2.56).
  • The risk for invasive ovarian cancer was not significantly higher, but this did go up with time, such that the longer the follow up period since first IVF, the higher the risk (after 15 years the SIR was 3.54, with 95% CI of 1.62-6.72).
  • After taking into account age, parity and cause of subfertility, the risk of borderline ovarian tumors was signficiantly over 4 times higher in the IVF group than the comparison group of similarly subfertile women who did not undergo IVF (hazard ratio HR 4.23, with 95% CI 1.25-14.33).
  • After similar adjustments, the risk of cancerous ovarian tumors was also significantly over 2 times higher in the IVF group than the comparison group of similarly subfertile women who did not undergo IVF (HR 2.14, 95% CI 1.07-4.25).
The authors conclude that:
"Ovarian stimulation for IVF may increase the risk of ovarian malignancies, especially borderline ovarian tumours."
They call for "more large cohort studies ... to confirm these findings and to examine the effect of IVF treatment characteristics".
Van Leeuwen told the BBC that "the absolute risk of these tumours is very low. But there is an increased risk of a borderline malignant tumour that needs surgery."
She said doctors should tell women about this risk but not overstate it.
Written by Catharine Paddock PhD

 
Design by Free WordPress Themes | Bloggerized by Lasantha -